Reported 1 day ago
Arvinas, Inc. (ARVN) presents a compelling investment case, trading at $6.50 while holding $954M in cash, significantly above its market cap. The company’s breast cancer drug, vepdegestrant, although not a blockbuster, retains value as a treatment option. With a sum-of-the-parts valuation exceeding $20/share and potential catalysts including ASCO data releases and Pfizer's involvement, the stock poses an attractive risk/reward scenario, despite current corporate governance issues.
Source: YAHOO